Two Drugs (#Apalutamide and #Enzalutamide) Offer Hope Against a Tough-to-Treat Prostate Cancer
THURSDAY, Feb. 8, 2018 -- Two cancer drugs can stall the progression of a particularly hard-to-treat form of prostate cancer, a pair of new trials shows. Both a newly developed drug called apalutamide and an already approved drug called...
Men with prostate cancer who get the gland removed may be just as likely to suffer erectile dysfunction and urinary incontinence with robotic surgery as with other operations, a UK study suggests.Reuters Health Information
Decipher testing recognized as standard-of-care in management of prostate cancer patients SAN DIEGO, Feb. 22, 2018 -- (Healthcare Sales &Marketing Network) -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced tha... Diagnostics, Oncology GenomeDx Biosciences, NCCN, Decipher Prostate, Prostate Cancer
CONCLUSIONS: Our results suggested that down-regulation of SPOP promoted OS cells migratory and invasive ability via modulating the "PI3K/Akt/NF-κB" signaling pathway. Thus, SPOP could be a promising drug target for the treatment of OS invasion. PMID: 29461588 [PubMed - in process]
Publication date: Available online 21 February 2018 Source:The Journal of Molecular Diagnostics Author(s): Anieta M. Sieuwerts, Bianca Mostert, Michelle van der Vlugt-Daane, Jaco Kraan, Corine Beaufort, Mai Van, Wendy J.C. Prager, Bram De Laere, Nick Beije, Paul Hamberg, Hans M. Westgeest, Metin Tascilar, Luc Y. Dirix, Wendy Onstenk, Ronald de Wit, Martijn P. Lolkema, Ron H.J. Mathijssen, John W.M. Martens, Stefan Sleijfer Recent reports have emphasized the clinical relevance of detecting the androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs). Our aim was to set up a validated multicenter pipelin...
Conclusion Our results suggest that specific topographic criteria of TZ and AS prostate cancers could add independent information to the usual diagnostic criteria in prostate MRI. Transrectal ultrasound fusion-targeted biopsies based on these specific criteria improve volume estimation of prostate cancers with substantial impact for prognosis and treatment planning.
Publication date: Available online 22 February 2018 Source:Pathology - Research and Practice Author(s): Nam Jin Yoo, Min Sung Kim, Ju Hwa Lee, Chang Hyeok An, Sug Hyung Lee
(Reuters Health) - Men with prostate cancer who get the gland removed may be just as likely to suffer after-effects like erectile dysfunction and urinary incontinence with robotic surgery as with other operations, a UK study suggests.
The observed narrowing of racial disparities in prostate cancer outcome since the advent of PSA screening is not as large as previously believed.